Key result
RNA-binding protein dysfunction is a potential mechanism of neurodegeneration in multiple sclerosis, representing a target for novel therapies to attenuate irreversible central nervous system damage.
Why the study?
Neurodegeneration underlies disease progression in multiple sclerosis, and studying RNA-binding protein dysfunction addresses a gap in understanding MS pathogenesis to help generate novel therapies.
This review highlights mechanisms of neurodegeneration in multiple sclerosis, focusing on RNA-binding protein dysfunction as a potential target for novel therapies.
RNA-binding protein dysfunction may offer a novel MS neurodegeneration target; leaves open whether modulation alters progression in trials.
Neurodegeneration in multiple sclerosis (MS) is believed to underlie disease progression and permanent disability. Many mechanisms of neurodegeneration in MS have been proposed, such as mitochondrial dysfunction, oxidative stress, neuroinflammation, and RNA-binding protein dysfunction. The purpose of this review is to highlight mechanisms of neurodegeneration in MS and its models, with a focus on RNA-binding protein dysfunction. Studying RNA-binding protein dysfunction addresses a gap in our understanding of the pathogenesis of MS, which will allow for novel therapies to be generated to attenuate neurodegeneration before irreversible central nervous system damage occurs.
No takes yet. Share an insight, caveat, or question.
Libner et al. (2020) conducted a review in Multiple sclerosis. RNA-binding protein dysfunction was evaluated. RNA-binding protein dysfunction is a potential mechanism of neurodegeneration in multiple sclerosis, representing a target for novel therapies to attenuate irreversible central nervous system damage.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: